Brain Tumor Organoid Modeling Service

Advancing neuro-oncology therapeutics is hindered by preclinical models that fail to capture the profound complexity of human brain tumors. While 2D cell lines lose crucial three-dimensional architecture and microenvironmental context, and animal models face limitations in cost, timelines, and species-specific differences, even first-generation organoids often fall short. Many standard organoid models lack a functional tumor microenvironment (TME)—including vasculature and immune components—and struggle to successfully culture more challenging tumors like lower-grade or IDH-mutant gliomas.

To overcome these hurdles, Creative Biolabs has developed a suite of next-generation brain tumor organoid platforms. We move beyond simple cell aggregates to create high-fidelity, patient-specific tumor ecosystems that preserve the critical histopathological, genomic, and cellular features of the original disease. Our models provide a clinically relevant, predictive bridge between your research and the patient.

Our Advanced Organoid Platforms: Tailored Models for Every Research Question

We recognize that a one-size-fits-all approach is insufficient for the complexities of brain cancer research. We offer a spectrum of meticulously characterized organoid models to meet your specific objectives.

1. Foundational Patient-Derived Organoids (PDOs)

Derived directly from patient tumor tissue, our PDOs are robust, scalable 3D models ideal for medium- and high-throughput screening (HTS) of compound libraries. These models serve as an excellent initial platform for evaluating drug efficacy and identifying lead candidates in a three-dimensional context that is superior to monolayer cultures.

Best For: Large-scale drug screening, initial efficacy/toxicity testing.

2. Genetically Engineered Cerebral Organoids (The neoCOR Platform)

To investigate the fundamental drivers of tumorigenesis, we offer a precision-engineered organoid platform. By employing advanced CRISPR-Cas9 technology, we can introduce specific gain-of-function and/or loss-of-function mutations into healthy human cerebral organoids.

This powerful approach allows for:

• Controlled study of tumor initiation and progression from a defined genetic event.
• Validation of specific genes as oncogenic drivers or therapeutic targets.
• Modeling tumor-normal tissue interaction, including invasion, within a single, self-contained system.

3. Advanced Tumor-Host Ecosystem Models (Our Premier Platform)

Inspired by the latest breakthroughs in the field, our premier offering involves the co-culture of patient tumor explants—intact, non-dissociated pieces of the tumor—within a living, iPSC-derived human cerebral organoid. This innovative methodology has demonstrated an exceptional ability to:

• Preserve the complex tumor ecosystem: This model uniquely maintains the parental tumor's architecture and critical stromal components, including tumor-associated macrophages (TAMs), T-cells, and endogenous microvasculature.
• Achieve high success rates: We successfully establish cultures from a broad range of CNS cancers, including aggressive glioblastomas, historically difficult-to-culture lower-grade and IDH-mutant gliomas, pediatric tumors, and brain metastases.
• Offer unparalleled predictive power: By maintaining the complex interplay of tumor and stromal cells, this model provides the most physiologically relevant data for predicting patient-specific therapeutic responses

Empowering the Full Spectrum of Neuro-Oncology Research

Our brain tumor organoid models provide actionable insights across the entire therapeutic development pipeline.

• Therapeutic Efficacy Testing: Evaluate the effectiveness of small molecules, biologics, and immunotherapeutic agents in a biologically relevant 3D context.
• Personalized Medicine & Stratification: Screen patient-derived organoids against a panel of approved or investigational drugs to identify the most effective treatment strategy for an individual.
• Investigating Drug Resistance: Model the emergence of acquired resistance and screen for compounds capable of overcoming it.
• Tumor Invasion and Metastasis: Utilize our advanced co-culture models to study the molecular mechanisms driving tumor cell invasion into surrounding neural tissue.
• Biomarker Discovery and Validation: Identify and validate novel prognostic or predictive biomarkers from organoids that closely mirror the parental tumor.
• Mechanism of Action (MoA) Studies: Elucidate the specific cellular and molecular pathways targeted by your therapeutic candidate.

Our Workflow

Propel Your Brain Tumor Research Forward

Leverage the predictive power of our advanced Brain Tumor Organoid models to de-risk your programs and accelerate the path to clinical translation.

Discuss Your Project With An Expert

Reference

1. Xu, Can et al. "Development of glioblastoma organoids and their applications in personalized therapy." Cancer biology & medicine vol. 20,5 (2023): 353–368. doi:10.20892/j.issn.2095-3941.2023.0061. Distributed under Open Access License CC BY 4.0. The original image was modified.